MDP — Medexus Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- CA$129.38m
- CA$144.11m
- $108.33m
Brief: Medexus Announces Renewal And Expansion Of Canadian Distribution Agreement For Nyda
Brief: Medexus Submits Application To List On The Nasdaq
Brief: Medexus Pharma Enters Into Exclusive License To Register, Commercialize Triamcinolone Hexacetonide In U.S With Ethypharm
Brief: Medexus Pharmaceuticals Reports Operating And Financial Results For The Three- And Six-Month Periods Ending September 30, 2020
Brief: Medexus Reaches 50% Enrollment In Ixinity Phase 4 Clinical Trial Targeting Label Expansion For Pediatric Hemophilia B Patients
Brief: Medexus Reports Health Canada Approval Of Gleolan® (5-Ala) For Use In Guided Surgical Resection Of High-Grade Gliomas
Canada Research Roundup: Airboss of America, Hydro One, Total Energy Services
Brief: Medexus Pharmaceuticals Reports Q1 Revenue Of $27.5 Mln
Brief: Medexus Pharma Reports Record Revenue Of $25.6 Mln And $4.2 Mln Of Adj EBITDA* For Q4 Of Fiscal 2020
Brief: Medexus Provides Update On Ixinity Acquisition And Overall Business In COVID-19 Environment
Brief: Medexus Announces $20 Million Asset-Based Credit Facility
Brief: Medexus Says Triamcinolone Hexacetonide Injectable Suspension Approved For Public Reimbursement In Canada
Canada Research Roundup: Centerra Gold, Medexus Pharmaceuticals, Savaria
Brief: Medexus Provides A Business Update And Outlines Response To Covid-19 Pandemic
Brief: Aptevo Therapeutics Sells Ixinity Hemophilia B Therapy For Estimated Proceeds In Excess Of $100 Million
Brief: Medexus Expands Its US Product Portfolio By Acquiring The Hematology Asset Ixinity
Brief: Medexus Pharmaceuticals Reports Q3 REVENUE OF C$16.2 MILLION
Brief: Medexus Pharmaceuticals Qtrly Revenue Was $16.4 Mln Compared To $3.4 Mln For Fiscal Quarter Ended Sept 30, 2018
Brief: Medexus Granted Priority Review Status For Gliolan By Health Canada